Voluntis (Euronext Paris, Mnemo: VTX – ISIN: FR0004183960), a company specialized in digital therapeutics, announces today that it has entered into a collaboration with AbbVie, a research-based global biopharmaceutical company, to enhance patient care coordination in immunology with innovative digital therapeutic software. Together the companies will leverage Voluntis’ proven Theraxium technology to make this new solution available to patients and providers in the United States.
“This collaboration illustrates the value of Theraxium in powering next-generation digital therapeutics in wide-ranging therapeutic areas.”
Pierre Leurent, CEO of Voluntis
About Voluntis
Voluntis creates digital therapeutics that empower people suffering from chronic conditions to self- manage their treatment every day, thus improving real-world outcomes. Combining mobile and web apps, Voluntis’ solutions deliver personalized recommendations to the patient and the care team that so that they can, for example, adjust treatment dosage, manage side effects or monitor symptoms. These real- time recommendations are based on digitized clinical algorithms. Leveraging its Theraxium technology platform, Voluntis has designed and operates multiple digital therapeutics. These include Insulia® and Diabeo® in diabetes as well as eCO and ZEMY in oncology. Voluntis has long-standing partnerships with leading life science companies such as Roche, AstraZeneca, Sanofi and Onduo. Based out of Boston and Paris, France, Voluntis is a founding member of the Digital Therapeutics Alliance.
Diabeo® is a registered trademark of Sanofi. Insulia® is a registered trademark of Voluntis. For further information: http://www.www.voluntis.com
Voluntis is traded on the Euronext Paris – Compartment C market
Ticker: VTX – ISIN:FR0004183960